Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q2 2024 · 10-Q
Revenue$4.12B$4.12B+14.5% vs Q2 2023 Net Income$322.00M$322.00M+19.3% vs Q2 2023 EPS Diluted$0.22$0.22+22.2% vs Q2 2023 Gross Profit$2,850,000,000+12.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Operating Cash Flowderived$813,000,000+23.6% Free Cash Flowderived$658,000,000+27.8% Margins · derivedGross margin69.2%−1.5 pt vs Q2 2023
Operating margin12.6%−1.7 pt vs Q2 2023
Net margin7.8%+0.3 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 1, 2024 · 32 d after period end